Wednesday, May 18

New blood test combined with image-based prostate cancer screening reduces harms and costs

Tobias Nordström. Photo: Stefan Zimmerman

“Our evidence provides support for using Stockholm3 as an additional test in MRI-based screening, which could be evaluated through one of the OPT pilots,” says Tobias Nordström, associate professor of urology at the Department of Clinical Sciences, Danderyd Hospital at Karolinska Institutet, who is the principal investigator for the STHLM3MRI trial and a co-author of the cost-effectiveness study.

Wider application to other countries

The current health economic evaluation is specific to Sweden, but the simulation model used in this study is open source and can be readily adapted to assess the use of Stockholm3 and MRI in other countries. The Stockholm3 test is available for clinical use in Sweden, Norway, Denmark, Finland, Spain and Germany, and will be made available in additional European countries in 2022.

The research was financed by the Swedish Research Council, the Swedish e-Science Research Centre (SeRC), the Swedish Prostate Cancer Federation, Karolinska Institutet and The Swedish Cancer Society. One of the co-authors, Henrik Grönberg, has five prostate cancer diagnostic-related patents pending. Another co-author, Martin Eklund, is named on four of these patent applications. Karolinska Institutet collaborates with A3P Biomedical in developing the technology for the Stockholm3 test. Henrik Grönberg, Martin Eklund and Tobias Nordström own shares in A3P Biomedical.

Publication

“Cost Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study”. S. Hao, E. Heintz, E. Östensson, A. Discacciati, F. Jäderling, H. Grönberg, M. Eklund, T. Nordström, M. Clements. European Urology, online 26 January 2022, doi: 10.1016/j.eururo.2021.12.021.

Reference-news.ki.se

Leave a Reply

Your email address will not be published.